IFNA1 and metastatic melanoma: Similarly, the USFDA approved IFN-α for treatment for hairy cell leukemia and IL-2 for metastatic kidney cancer and metastatic melanoma in 1986 and 1992 respectively, which have been shown to enhance the production of T cells in patients.